There were 2,114 press releases posted in the last 24 hours and 440,815 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image